

Distinct Gut and Vaginal Microbiota Profile in Women with Recurrent Implantation Failure and Unexplained Infertility

Nayna Patel

Akanksha Hospital and Research Institute

Nidhi Patel

Gujarat Biotechnology Research Centre

Sejal Patel

Gujarat Biotechnology Research Centre

Neelam Nathani

Gujarat Biotechnology Research Centre

Ramesh Pandit

GBRC: Gujarat Biotechnology Research Centre

Molina Patel

Akanksha Hospital and Research Institute

Niket Patel

Akanksha Hospital and Research Institute

Chaitanya Joshi

GBRC: Gujarat Biotechnology Research Centre

Dr Bhavin Parekh (✉ bp2580@gmail.com)

Akanksha Hospital <https://orcid.org/0000-0001-6237-4727>

Research

Keywords: Gut microbiota, Vaginal microbiota, Implantation failure, Infertility, Endometrium

Posted Date: July 14th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-672281/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Women's Health on April 12th, 2022.
See the published version at <https://doi.org/10.1186/s12905-022-01681-6>.

1 **Distinct gut and vaginal microbiota profile in women with Recurrent**
2 **Implantation Failure and Unexplained Infertility**

3 **Author details**

4
5 Nayna Patel¹, Nidhi Patel², Sejal Pal¹, Neelam Nathani², Ramesh Pandit², Molina
6 Patel¹, Niket Patel¹, Chaitanya Joshi² and Bhavin Parekh^{1*}

7 1. Akanksha Hospital and Research Institute, Lambhvel Road, Lambhvel, Anand,
8 Gujarat 387310, India.

9 2. Gujarat Biotechnology Research Centre (GBRC), Gandhinagar, Gujarat,
10 382011, India.

11

12 **Author's information**

13 E-mail addresses of authors:

14 *Correspondence: Dr Bhavin Parekh: bp2580@gmail.com

15 Nayna Patel: nayana@ivf-surrogate.com

16 Nidhi Patel: patelnidhi702@gmail.com

17 Sejal Pal: sejalpal15@gmail.com

18 Neelam Nathani : neelam.nathani13@gmail.com

19 Ramesh Pandit : panditrameshj@gmail.com

20 Molina Patel: Drmolinapatel@gmail.com

21 Niket Patel: niketslam@gmail.com, Dr Chaitanya Joshi: director.gbrc@gmail.com

22 Abbreviations

23

24 AMH, Anti-Müllerian hormone; ASV, Amplicon sequence variants; BMI, Body
25 mass index; ET, Embryo transfer; (F/B) ratio, *Firmicutes* to *Bacteroidetes* ratio;
26 ICSI, Intracytoplasmic Sperm Injection; IL-6, Interleukin 6, IL-10 , Interleukin 10,
27 IVF, *In vitro* fertilization; *L. delbrueckii*, *Lactobacillus delbrueckii*; *L.*
28 *equicursoris*, *Lactobacillus equicursoris*; *L. fermentum*, *Lactobacillus fermentum*;
29 *L. gasseri*, *Lactobacillus gasseri*; *L. Iners*, *Lactobacillus iners*; *L. jensenii*,
30 *Lactobacillus jensenii*; *L. reuteri*, *Lactobacillus reuteri*; *L. ruminis*, *Lactobacillus*
31 *ruminis*; *L. salivarius*; *Lactobacillus salivarius*; *L. vaginalis*; *Lactobacillus*
32 *vaginalis*; LDA, Linear discriminant analysis; LEfSe, linear discriminant analysis
33 effect size; LPS, lipopolysaccharides; MAMPs, Microbe-associated molecular
34 patterns; OTU, operational taxonomic units; PERMANOVA, Permutation
35 multivariate analysis of variance; PCoA, Principle Coordinate Analysis; RIF,
36 Recurrent implantation failure; SCFA, short-chain fatty acids; 16S rna, 16S
37 ribosomal RNA; TLRs, toll-like receptors, TMAO Trimethylamine N-oxide; TNF-
38 α , Tumor Necrosis Factor- α ; UE, Unexplained infertility.

39

40 **Abstract**

41

42 **Background:** Implantation failure limits the success rate of natural and *in*
43 *vitro* fertilization (IVF)-assisted conceptions. Evidence suggests dysbiosis in the
44 female reproductive tract impacts implantation failure. However, whether gut
45 dysbiosis influences implantation failure and whether it accompanies reproductive
46 tract dysbiosis remains unexplored.

47

48 **Method:** We recruited 11 fertile women as the controls, and a cohort of 20 women
49 diagnosed with implantation-failure associated infertility, which included 10
50 women diagnosed with recurrent implantation failure (RIF), and 10 women
51 diagnosed with unexplained infertility (UE). Using next-generation amplicon
52 sequencing, we compared the diversity, structure, and composition of fecal and
53 vaginal bacteria of the controls with that of the infertile cohort. While we
54 sequenced fecal samples of all the participants (n=31), we could only
55 sequence 8 vaginal samples in each group (n=24).

56

57 **Results:** Compared with the controls, α -diversity of the gut bacteria, analysed by
58 Chao 1 and Shannon indices, among the infertile groups declined ($p < 0.05$). β -
59 diversity between the controls and infertile cohort, measured by both Bray-Curtis
60 and Jaccard distances, differed significantly ($p < 0.05$). Taxa analysis of the gut
61 bacteria revealed enrichment of Gram-positive bacteria, mainly of the

62 phylum *Firmicutes*, in the RIF group. In contrast, Gram-negative bacteria were
63 relatively more abundant in the UE group. Additionally, mucus-producing
64 bacteria genera such as *Prevotella* and *Sutterella* declined in the infertile
65 cohort ($p < 0.05$). Intriguingly, significant enrichment ($p < 0.05$) of the
66 genus *Hungatella*, associated with trimethylamine N-oxide (TMAO) production,
67 occurred in the infertile cohort. Vaginal microbiota was dominated by *L.*
68 *iners* across the groups, with the UE group showing the highest levels. Of the three
69 groups, the RIF group had the least diverse vaginal microbiota. Taxa analysis
70 showed higher levels of anaerobic bacteria such
71 as *Leptotrichia*, *Snethia*, and *Prevotella* in the controls.

72

73 **Conclusion:** We posit that in the setting of the compromised gut mucosal barrier,
74 the phyla *Firmicutes* generates TNF- α -driven systemic inflammation, leading to
75 RIF, whereas an overload of Gram-negative bacteria induces IL-6-driven systemic
76 inflammation, leading to UE. Additionally, *Hungatella*-induced elevation
77 of TMAO levels causes platelet hypercoagulability, synergistically contributing to
78 implantation failure. Finally, vaginal dysbiosis does not appear to co-occur with
79 gut dysbiosis.

80

81 **Key Words: Gut microbiota, Vaginal microbiota, Implantation failure,**
82 **Infertility, Endometrium**

83

84

85 **1. Introduction**

86 Infertility, defined as a failure to conceive after 1 year of appropriately timed
87 unprotected intercourse, is a distressing and costly reproductive disorder that
88 affects up to 15% of couples globally (Kamel 2010). Some known causes of
89 infertility include pelvic diseases, peritoneal factors, cervical factors, ovulatory
90 disorders, reproductive aging of women, and male factors (Lindsay and Vitrikas
91 2015).

92 Despite this knowledge, some couples are diagnosed as having unexplained
93 infertility (UE) because the underlying mechanism(s) remain undefined even after
94 assessment of ovulatory function, tubal patency, and sperm parameters (Bellver,
95 Soares et al. 2008). Frustratingly, many of the infertile couples undergo multiple
96 unsuccessful assisted reproduction technology (ART) cycles (i.e., IVF and/or
97 intracytoplasmic sperm injection (ICSI)) and are thus diagnosed as having repeated
98 implantation failure (RIF) (Bellver, Soares et al. 2008, Simon and Laufer 2012,
99 Polanski, Baumgarten et al. 2014). Yet another subgroup of infertile couples,
100 diagnosed as recurrent pregnancy loss (RPL), exists that conceive several times
101 (≥ 3), but miscarriage occurs each time before gestational week 28, although
102 controversies exist on its definition (Christiansen, Nielsen et al. 2006, El Hachem,
103 Crepaux et al. 2017). It has been argued that RIF and RPL represent the same
104 condition spectrum (Christiansen, Nielsen et al. 2006).

105 Pathologies of all these enigmatic conditions converge on mechanisms by which
106 the embryo fails to implant in the uterus—also called implantation failure
107 (Graham, Seif et al. 1990, Christiansen, Nielsen et al. 2006, Bellver, Soares et al.
108 2008, Simon and Laufer 2012). It is the main limiting factor for natural and *in vitro*
109 fertilization (IVF)-assisted pregnancies (Bellver, Soares et al. 2008, Hernández-
110 Vargas, Muñoz et al. 2020). Failed implantation involves a triumvirate of a poor
111 quality embryo and an unreceptive endometrium and ill-timed embryo-
112 endometrium interaction, of which unreceptive endometrium appears to be the
113 most critical factor. (Simon and Laufer 2012). In fact, unreceptive endometrium
114 has been implicated in two-thirds of all the failures (Simon and Laufer 2012).
115 While multiple factors that disrupt endometrium receptivity, including steroidal
116 hormonal imbalance, thrombotic abnormalities, hyperhomocysteinemia, and
117 immune dysfunctions, have been identified, much remains recondite (Bellver,
118 Soares et al. 2008, Simon and Laufer 2012, Cho, Kim et al. 2019).

119 The reproductive tract bacteria influence implantation failure of endometrial origin
120 (Al-Nasiry, Ambrosino et al. 2020). For example, women with non-*Lactobacillus*-
121 dominated microbiota in a receptive endometrium had decreased implantation rates
122 than women with a *Lactobacillus*-dominated (>90%) microbiota (Moreno,
123 Codoñer et al. 2016). Chlamydia species in the endocervix of women undergoing
124 IVF-ET were correlated with implantation failure (Witkin, Sultan et al. 1994).

125 Increasingly researchers are exploring how the local microbiota influences
126 physiology at distal sites, especially how the gut bacteria, the densest and most
127 diverse bacterial communities of the body, impact distal organs, including the brain
128 and lungs, leading to the notions of the gut-brain axis and gut–lung microbiota axis
129 (Ravel and Brotman 2016, Budden, Gellatly et al. 2017). However, hitherto, gut
130 bacteria’s role in implantation failure of endometrial origin remains unexplored, let
131 alone the gut-reproductive tract microbiota axis, even though a compelling
132 rationale exists. Indeed, the gut bacteria impact the immune system, hormonal
133 homeostasis, and the coagulation system—all of which mediate implantation
134 success (Alexander, Targan et al. 2014, Baker, Al-Nakkash et al. 2017, Vinchi
135 2019). The comorbidity of gut disorders (e.g., celiac disease) with infertility
136 disorders, including recurrent pregnancy loss, allude to a role of ‘gut-reproductive
137 tract axis’ in implantation failure (Tersigni, D’Ippolito et al. 2018).

138 Hence we investigated whether gut dysbiosis occurs in women with implantation
139 failure, and if so, whether it accompanies vaginal dysbiosis, which usually involves
140 a decline in either the levels of *Lactobacillus* or protective species of *Lactobacillus*
141 and a simultaneous rise in the diversity and density of other bacteria (Madhivanan,
142 Alleyn et al. 2015, Amabebe and Anumba 2018, Wang, Fan et al. 2020). To this
143 end, by using 16S rRNA gene sequencing, we compared the diversity, structure

144 and taxonomic composition of the fecal and vaginal microbiota of fertile women
145 with that of infertile women with a history of RIF and UE.

146

147 **2. Materials and Methods**

148 **2.1 Study participants**

149 For this retrospective, single-center cohort study, fertile and infertile women,
150 referred to Akanksha Hospital and Research Institute between September 2018 and
151 February 2019, were recruited and divided into three groups: the control, RIF, and
152 UE groups. The RIF group's inclusion criteria were women who could not
153 conceive after ≥ 2 fresh IVF-embryo transfer cycles/ Intracytoplasmic Sperm
154 Injection (ICSI) or had ≥ 3 consecutive miscarriages. UE was diagnosed if a cause
155 remains undefined after our routine fertility tests with the following criteria:
156 infertility of more than 1 year, normal male partner, normal menstrual rhythm with
157 regular ovulation, and normal hormonal tests (i.e., thyroid, prolactin, AMH)
158 Exclusion criteria included diabetes, polycystic ovary syndrome and
159 endometriosis, diarrhea, ongoing pregnancy, addiction (e.g., drugs, alcohol,
160 tobacco etc.) and the use of antibiotics within at least two weeks before sample
161 collection.

162 **2.2 Ethical approval and Consent to participate**

163 We performed all the sampling and experiments with the approval of the local
164 Ethics Committee of Sat Kaival Hospital Pvt. Ltd (EC2013/053). Participants gave
165 their oral and written informed consent for fecal and vaginal sample collections

166 and subsequent microbiological analysis. We recorded and compared participants'
167 characteristics (**Table 1**).

168 **2.3 Sample Collection**

169 The fecal and vaginal samples were freshly and simultaneously collected.
170 Participants collected the fecal samples in a sterile plastic container with a tight
171 closing lid. To collect the vaginal samples, using a sterile swab stick, clinicians
172 thoroughly wiped the posterior fornix of the vagina of the participants. These
173 swabs were stored in sterile vials. Both types of samples were packaged and first
174 placed in a frozen storage at -20°C in the hospital and later, within 24 hours,
175 transported on ice to be stored at -80°C at Gujarat Biotechnology Research Centre
176 (GBRC) for further analysis.

177

178 **2.4 DNA extraction**

179 DNA extraction was performed from approximately 200 mg of fecal samples and
180 ~1ml of thoroughly vortexed swab sample using QIAamp DNA Stool Mini Kit
181 according to the manufacturer's instructions. Total DNA was eluted in 30 μL of
182 AE buffer. DNA concentration was quantified fluorometrically with a Qubit 2.0
183 dsDNA HS Assay kit. DNA was stored at -20°C for further procedures.

184

185

186 **2.5 Library preparation and 16s rRNA Sequencing**

187 The V2-V3 hypervariable regions of the 16S rRNA gene were amplified using
188 fusion primers, 101 F5'ACTGGCGGACGGGTGAGTAA 3' and 518 R
189 5'CGTATTACCGCGGCTGCTGG 3'. Amplicon libraries were purified using the
190 Agencourt AMPure XP (Beckman Coulter). For quality control, we used
191 Bioanalyzer with a DNA-HS assay kit. All the libraries were quantified using
192 Qubit fluorimeter v4.0 and were pooled into equimolar concentrations. Clonal
193 amplification (Emulsion PCR) sequencing was performed on the Ion S5 system
194 using the Ion 520/530 kit OT2 (ThermoFisher Scientific) with Ion One Touch 2
195 system, which uses a 530 chip on Ion S5 plus sequencer according to the
196 manufacturer's instructions.

197 **2.6 Bioinformatics and Statistical analysis**

198 **Diversity**

199 Microbial community richness and diversity was evaluated by α -diversity that
200 included Chao1 and Shannon indices. The Kruskal–Wallis test used to determine
201 statistical differences between the three groups. The Mann–Whitney U test was
202 used to determine the influence of diet on α -diversity. β -diversity, differences in
203 microbial community structures between the three groups, was analysed using
204 Principle Coordinate Analysis (PCoA) based on Bray-Curtis and Jaccard distances,

205 and the statistical difference between the groups was calculated using non-
206 parametric permutational multivariate analysis of variance (PERMANOVA).

207 QIIME2 software was used to calculate alpha and beta diversity indices. The
208 demultiplexed sequences were uploaded to QIIME2 environment, and denoising
209 was carried out using DADA2. Amplicon sequence variants (ASVs) were
210 predicted at a minimum sampling depth of 25000 for Gut datasets, and 9000 for the
211 vaginal datasets. The predicted ASVs were taxonomically classified using the pre-
212 trained classifier of the full 16S rRNA gene sequence of the SILVA database.

213 **Taxonomic structure**

214 We analysed the gut microbiota at the community level to determine differences in
215 the microbial composition between groups and to identify taxa with significantly
216 different abundance (relative abundance > 0.001 and $P < 0.05$). Additionally, linear
217 discriminant analysis effect size (LEfSe) method was employed to identify species
218 with significant differences in abundance between the three groups ($|LDA| > 3$ and
219 $P < 0.05$). Kruskal–Wallis and Mann–Whitney U tests were performed
220 for computing statistical differences between the groups at taxonomic levels in the
221 study viz., three major groups and the infertile cohort versus controls using
222 STAMP v2.1 software (Parks et al., 2014).

223 Continuous data are presented as mean \pm standard deviation (SD) or frequencies
224 (number and percentages), calculated using GraphPad Prism statistical software
225 6.0. To determine statistical differences in subjects' characteristics between
226 groups, we performed one-way ANOVA followed by post-hoc Tukey testing.

227

228 **3. Results**

229 **3.1 Clinical Characteristics among the Control, RIF, and UE Groups**

230 We included 31 study subjects, comprising 11 fertile women, enrolled as the
231 control group, 10 women with a history of RIF, and 10 women with a history of
232 UE (**Table 1**). Comparisons of the mean age between the three groups showed that
233 the controls were statistically significantly younger than the RIF group ($F=6.8$, p
234 <0.01), while the UE group was older than the controls and younger than the RIF
235 group, although both differences were statistically insignificant (**Table 1**). The
236 average BMI was not significantly different between the controls and the UE group
237 and between the RIF and UE groups but was significant between the controls and
238 the RIF group ($F=3.7$, $p<0.05$) (**Table 1**). Among women with RIF, eight were
239 nullipara (80%), and two were nulligravida (20%), while all women with UE
240 (100%) were nullipara. There were more vegetarian participants in the UE group (9
241 of 10; 90%) than in the RIF group (4 of 10; 40%) and the controls (4 of 11; 36%)
242 (**Table 1**).

243

244 **3.2 Metagenomics Findings of Gut and Vaginal bacteria**

245 In total 31 fecal samples and 24 vaginal swab samples, sequencing of the V2-V3
246 region of the 16S rRNA gene created 235810 sequences, with an average of 1,01,
247 767 sequences, and 178260 high-quality sequences, with an average of 3,76,012

248 sequences, per sample for fecal and vaginal samples respectively. Based on the
249 results of the operational taxonomic units (OTUs) analysis, rarefaction curves
250 show that the sequencing depth was adequate to analyse the gut and vaginal
251 bacteria in the three groups (**Figures S1 (a), (b) and Figures S2 (a), (b)**).

252

253 **3.3 Richness and diversity of Gut bacteria**

254 We performed bacterial diversity analyses by comparing the richness using Chao 1
255 and evenness using the Shannon index for the fecal microbial communities
256 between the three groups. We found that richness differed significantly between
257 the three groups (Chao 1 index (Kruskal–Wallis test, $p= 0.049$)) (**Figure 1(a)**).
258 Precisely, the controls had a significantly higher richness than the RIF group
259 ($p_{\text{Chao 1}} = 0.04$) and UE group ($p_{\text{Chao 1}} = 0.03$). Richness was similar between
260 RIF and UE groups ($p_{\text{Chao 1}} = 0.75$). We discovered that evenness differed
261 significantly between the three groups: Shannon index (Kruskal–Wallis test, $p =$
262 0.003) (**Figure 1(b)**). Specifically, the controls had more evenness than the RIF
263 ($p_{\text{Shannon}} = 0.006$) and the UE groups ($p_{\text{Shannon}} = 0.002$). In contrast, evenness
264 was similar between the RIF and the UE groups ($p_{\text{Shannon}} = 0.65$). Interestingly,
265 the diet did not affect alpha diversity ($p_{\text{Shannon}} = 0.165$) (**Figure 3S**).

266 Regarding the bacterial community structure differences, the PCoA plot of the
267 Bray-Curtis and Jaccard dissimilarity showed that bacteria of the RIF and UE

268 groups overlapped and that both groups differed markedly from the controls
269 **(Figures 2(a), (b))**. In the PCoA plot based on Bray-Curtis distances, the first and
270 second axes of the PCoA explained 21.5% of the total variance with a significant
271 difference (PERMANOVA, $P < 0.05$, $R^2 = 0.12$; **Figures 2(a)**). Showing the similar
272 clustering pattern, in the Jaccard based PCoA plot, the first and second axes
273 explained 23.4% of the total variance with a significant difference
274 (PERMANOVA, $P < 0.05$, $R^2 = 0.10$; **Figures 2(b)**).

275

276 **3.4 Taxonomic analysis of Gut bacteria**

277 After excluding the sequences that were present in less than 3%, we clustered the
278 high-quality sequences into OTUs and assigned taxonomic identities.
279 Consequently, we found 550 OTUs pertaining to 481 genera, 265 families, 156
280 orders, 68 classes, 715 species and 28 phyla. To evaluate the contribution of
281 different taxa to diversity and composition, we calculated the relative abundance of
282 taxa at the phylum, family and genus levels. Except at the genus level, we could
283 not find statistically significant alteration of particular taxa at any other levels.
284 Though, noticeable trends from a clinical point of view were still apparent in the
285 data.

286 Across all 31 participants, the phyla level composition, represented by read
287 percentages, showed usual human microbiota structures. Overall, among the
288 detected 28 phyla, the four most abundant microbes were *Firmicutes* (85.10%),
289 *Bacteroidetes* (7.70%), *Proteobacteria* (4.75%), and *Actinobacteria* (1.8%)
290 **(Figure 3(a))**. With a relative abundance of less than 1%, the remaining bacterial
291 population belonged to four phyla, including *Verrucomicrobia*, *Tenericutes*,
292 *Cyanobacteria*, and *Chloroflexi*.

293 Firmicutes were abundant (7-9 %) in the RIF group than both the control and UE
294 groups. *Firmicutes* were only slightly more abundant (2%) in the UE group than
295 the controls. *Bacteroidetes* were depleted (50% less) in the RIF group than the
296 other two groups. In contrast, the control and UE groups had the same levels of
297 *Bacteroidetes*. *Proteobacteria* were relatively less abundant (4-7% less) in the RIF
298 group than the control and UE groups **(Figure 3 (a))**. Among the three groups, the
299 UE group had the highest levels of *Proteobacteria*, almost 2 fold higher than the
300 controls. *Actinobacteria* were depleted in the UE group (~4 fold less) compared to
301 the other two groups, with the RIF group showing the highest abundance amongst
302 all the groups, with 2 fold more abundance than the control group **(Figure 3(a))**.

303 The dominant bacterial families for all the subjects in the descending order of
304 abundance were *Lachnospiraceae*, *Ruminococcaceae*, *Bifidobacteriaceae*,

305 *Erysipelotrichaceae*, *Lactobacillaceae*, *Prevotellaaceae*, *Vellinollaceae* and
306 *Enterobacteriaceae* (**Figure 3(b)**). The levels of *Lachnospiraceae* and
307 *Ruminococcaceae* were similar between the three groups. Notably, the levels of
308 *Lactobacillaceae* and *Prevotellaaceae* families were highest in the controls as
309 compared to the other two infertile groups. *Bacteroidaceae*, *Vellinollaceae* and
310 *Enterobacteriaceae* were highest in the UE group compared to the RIF and control
311 groups, while *Bifidobacteriaceae* and *Erysipelotrichaceae* families were highest in
312 the RIF group as compared to the control and UE groups (**Figure 3(b)**).

313 We further determined statistical differences in the specific bacterial genera of the
314 three groups. Among 481 genera, the 6 were statistically significantly ($p < 0.05$)
315 different: *Bacteroides*, *Prevotella 9*, *Hungatella*, *Ruminococcaceae UCG-004*,
316 *Ruminococcaceae UCG-010*, and *Sutterella*. Aside from *Bacteroides* and
317 *Prevotella 9*, the abundance of the other 5 genera, while statistically significant
318 ($p < 0.05$), occurred in much lower proportions ($< 1\%$). Notably, *Bacteroides* and
319 *Hungatella* were abundant in the infertile cohort, especially in the UE group, than
320 the controls (**Figure 3(c)**).

321 *Bacteroides* and *Prevotella 9*, the two most highly abundant genera, varied
322 significantly between the three groups. Compared to the controls, the relative
323 abundance of *Prevotella 9* plunged noticeably in the RIF group (7 fold), and the

324 UE group (8 fold), and the relative abundance of *Bacteroides* rose in the RIF group
325 (1.5 fold) and UE group (3.2 fold) (**Figure 3(c)**). When we compared the infertile
326 group against the controls, we found that in the infertile cohort *Prevotella* 9,
327 *Ruminococcaceae* UCG-004, *Ruminococcaceae* UCG-010 ($p < 0.05$) declined,
328 whereas *Bacteroides*, *Dorea*, oral clone FR58 and *Peptoniphilus* increased
329 ($p < 0.05$) (**Figure 4S**).

330 **3.5 LEfSe analysis**

331 LEfSe analysis was performed to assess the differentially abundant communities in
332 the three groups (**Figure 4 (a), (b)**). In the controls, we observed diverse microbial
333 communities with a high LDA score (Log10), with *Clostridia* showing the highest
334 LDA score > 9 ($p < 0.05$). In the RIF group, only *Eubacterium halli* showed the
335 highest dominance with an LDA score > 7 ($p < 0.05$). In the UE group,
336 unconventional *Firmicutes* such as *Veillonellaceae*, *Selenomonadales*, of the class
337 *Negativicutes*, showed the highest preponderance with an LDA score > 7 ($p < 0.05$).

338 **3.6 Metagenomics of vaginal bacteria**

339 Across the 24 vaginal samples, we found 384 distinct species belonging to 301
340 different genera classified in 135 different families, distributed into 10 phyla. We
341 compared taxa between the three groups. Given the small sample size, we could

342 not detect a significant statistical difference between them. Nonetheless, interesting
343 trends in the data were apparent from a clinical point of view.

344 **3.7 Taxonomic Analysis of Vaginal Bacteria**

345 In the descending order, the dominant phyla, among the 10 detected phyla,
346 included *Firmicutes*, *Fusobacteria*, *Proteobacteria*, *Actinobacteria*, *Bacteroidetes*,
347 and *Patescibacteria* (**Figure 5(a)**). Of these, *Firmicutes* accounted for the vast
348 majority of the vaginal bacteria in all the groups, with both the RIF (69%) and UE
349 (69.71%) groups showing similar relative abundance, which was higher than the
350 controls (53%). *Fusobacteria* (18% Vs. 0.07 Vs. 0.14) and *Bacteroidetes* (4.1%
351 Vs. 0.17 Vs. 0.92) were relatively abundant in the controls than the RIF and UE
352 groups. *Proteobacteria* were marginally more abundant in both RIF (15% Vs. 11%)
353 and UE (19% Vs. 11%) groups compared to the controls (**Figure 5(a)**).

354 The dominant families for all the groups in the descending order of abundance
355 were *Lactobacillaceae*, *Bifidobacteriaceae*, *Leptotrichiaceae*, and *Prevotellaceae*
356 (**Figure 5(b)**). *Lactobacillaceae* and *Bifidobacteriaceae* were present in all the
357 groups. Reflecting this trend at the phylum level, levels of *Lactobacillaceae* were
358 higher in all the groups, with UE (65.3%) and RIF (58.41%) women showing the
359 highest levels compared with the controls (47.2%).

360 At the genus level, 5 genera were detected, of which three were present in all the
361 groups (**Figure 5(c)**). *Lactobacillus* was the most dominant genus among them,
362 followed by *Gardnerella* and *Parvimonas*. *Gardnerella*, *Prevotella*, *Parvimonas*,
363 and *Sneathia* were relatively more abundant in the controls compared to the
364 infertile groups. Compared to the controls, *Lactobacillus* was relatively more
365 abundant in the RIF and the UE groups (2-fold).

366 At the species levels, *Sneathia amnii* (0.36%) was detected only in the control
367 groups. In contrast, *Lactobacillus iners AB-1* were present in all the groups, with
368 descending order of relatively high abundance in the following manner: the UE
369 group (62%), the controls (16%), and the RIF group (11.02%) (**Figure 5(d)**).

370 **3.8 LEfSe analysis**

371 We performed LEfSe analysis to assess the differentially abundant vaginal
372 bacterial communities in the three groups. We could only find significant
373 differences in the controls, with *Leptotrichia*, of the phylum *Fusobacteria*,
374 showing an LDA (Log10) score >3 (p<0.05) (**Figure 6**).

375 **3.9 Alterations of the genus Lactobacillus Species**

376 Within the genus of *Lactobacillus*, 9 species were identified. *L. gasseri*, *L. ruminis*,
377 and *L. iners AB-1* were found in all the groups, with *Lactobacillus iners AB-1*
378 being the most abundant species (**Figure 7**). Among these, *L. jensenii* and *L.*

379 *vaginalis* were only detected in the UE group, while *L.reuteri* was unique to the
380 RIF group. *L. equicursoris*, *L. fermentum* and *L. salivarius* were unique to the
381 controls.

382

383 **4. Discussion**

384 We compared, for the first time, the gut-vaginal microbiota axis of fertile women
385 with that of women diagnosed with RIF and UE. The core findings include i) the
386 infertile groups had gut dysbiosis as evident by low α -diversity indices and beta
387 diversity metrics; ii) the gut microbial composition of the RIF and UE groups
388 differed noticeably, with a set of Gram-positive taxa, mainly members of the
389 phylum *Firmicutes*, being dominant in the former group and a set of Gram-
390 negative bacteria, comprising members of the phylum *Proteobacteria* and the class
391 *Negativicutes*, of the phylum *Firmicutes*, being dominant in the latter group; iii)
392 butyrate-producing genera such as *Prevotella* declined in the infertile cohort; iv)
393 elevated levels of the genus *Hungatella* occurred in the infertile cohort, especially
394 in the UE; and v) the infertile cohort, especially the RIF group, had a
395 comparatively healthy vaginal microbiota than the controls.

396 Gut microbial richness and diversity, defined by α -diversity indices, declined
397 amongst the infertile groups, with the highest decline in the UE group. Studies
398 have suggested that reduced α -diversity, an important indicator of gut microbiome
399 health, indicates low-grade inflammatory disorders such as inflammatory bowel
400 disease, metabolic disorder and obesity (Ott and Schreiber 2006, Le Chatelier,
401 Nielsen et al. 2013, Al-Assal, Martinez et al. 2018). Of note, diet (vegetarian vs.
402 Non-vegetarian) had little influence on α -diversity. Although, a fine-grained

403 analysis showed vegetarian women had a higher proportion of the phyla
404 *Patescibacteria* and the genus *Bacteroides*, likely reflecting its role in the digestion
405 of plant fiber (Matijašić, Obermajer et al. 2014, Jang, Choi et al. 2017). Gut
406 dysbiosis was also reflected in beta diversity indices, suggesting a distinct bacterial
407 composition between the infertile cohort and the controls.

408 Notably, the reduction in the richness of gut bacteria in the RIF group was seen for
409 the phyla *Bacteroidetes* and *Proteobacteria* compared with the other groups.
410 Mirroring this, we observed a lower percentage of *prevotellaceae* (phylum
411 *Bacteroidetes*), *Veillonellaceae* (phylum *Proteobacteria*), *Enterobacteriaceae*
412 (phylum *Proteobacteria*). This was partly reflected at the genus level by a several-
413 fold decrease in the genus *Prevotella* (phylum *Bacteroidetes*) and a mild elevation
414 in *Bacteroidaceae* (phylum *Bacteroidetes*). In contrast, in the UE group, the
415 reduction in richness was seen mainly for the phyla *Actinobacteria* and marginally
416 for *Bacteroidetes*. In keeping with this, reduced levels of the *Bifidobacteriaceae*
417 family (Phylum *Actinobacteria*) were noted, and a marginal decline in the phyla
418 *Bacteroidetes* was reflected by the depletion of the *prevotellaceae* family (phylum
419 *Bacteroidetes*) and a modest rise in *Bacteroidaceae* (phylum *Bacteroidetes*).

420 Altogether, the data clearly indicate that the reduced microbial richness in the RIF
421 and UE groups is characterised by contrasting types of abundance at the taxa level.
422 Nonetheless, data showed a partial overlap at the genus level in that a relative

423 decline in the abundance of *Prevotella* and an increase in the abundance of
424 *Bacteroides* commonly occurred in both the groups. Since *Prevotella* builds the
425 protective gut mucosal barrier from short-chain fatty acids (SCFAs) such as
426 butyrate and *Bacteroides* impedes mucin synthesis by producing metabolites such
427 as succinate, acetate, and propionate, these findings suggest thinned mucosal
428 protection is the common abnormality in the infertile cohort. (Mejía-León and
429 Barca 2015). Of note, although not highly abundant in the infertile cohort,
430 *Ruminococcaceae* UCG-004 and *Ruminococcaceae* UCG-010, of the
431 *Ruminococcaceae* family and the genus *Sutterella* declined as well. These are also
432 butyrate- producing genera (Vital, Karch et al. 2017, Jennings, Koch et al. 2019,
433 Wang, Wichienchot et al. 2019).

434 When the mucus barrier is thinned, the gut bacteria and other microbe-associated
435 molecular patterns (MAMPs) come in direct contact with toll-like receptors
436 (TLRs), located in the gut epithelial cells such as the Paneth cells (Uchida,
437 Oyanagi et al. 2014, Okumura and Takeda 2017, Steimle, Michaelis et al. 2019).
438 TLRs recognise microbes and MAMPs, and subsequently elicit an immune
439 response, leading to localised and systemic inflammation, which can cause
440 implantation failure (Uchida, Oyanagi et al. 2014, Mejía-León and Barca 2015,
441 Okumura and Takeda 2017, Steimle, Michaelis et al. 2019).

442 We proffer the following hypotheses to explain how the gut dysbiosis in the
443 infertile groups causes implantation failure by separate mechanisms that promote
444 systemic inflammation. We posit that gut dysbiosis–induced metabolic
445 dysregulation plays a role in RIF. At the phyla level, abundances of *Bacteroidetes*
446 and *Proteobacteria* were lower. By contrast, *Firmicutes* and *Actinobacteria*'s
447 levels were higher in the RIF group compared with the other two groups--
448 indicating an obesity-associated microbiota profile (Koliada, Syzenko et al. 2017).
449 Obesity has been linked to an increase in *Firmicutes* to *Bacteroidetes* (F/B) ratio
450 (Verdam, Fuentes et al. 2013, Koliada, Syzenko et al. 2017).

451 Conversely, weight loss has been shown to normalise this ratio (Koliada, Syzenko
452 et al. 2017). The F/B ratio was elevated in six out of ten women in the RIF group.
453 In contrast, only two to three subjects had elevated F/B ratio in the other groups.
454 Unsurprisingly, the RIF group's mean BMI, highest among the three groups, was
455 in the obesity range (obesity ≥ 25 kg/m² for Asian Indians (Mahajan and Batra
456 2018)), which chimes with the fact that obesity is a risk factor for RIF(Zhang, Liu
457 et al. 2019).

458 Notably, the Clostridium XIVa cluster, of the *Firmicutes* phylum, whose members
459 comprise flagellated bacteria with a tendency to colonise mucus, play a critical role
460 in metabolic dysregulation such as obesity (including visceral
461 adiposity) (Lopetuso, Scaldaferri et al. 2013, Verdam, Fuentes et al. 2013,

462 Jennings, Koch et al. 2019). Indeed, a trend towards an increase in the relative
463 abundance of *Firmicutes* genera in this cluster such as *Lachnoclostridium*, *Dorea*,
464 *Ruminococcus 2*, and *Eubacterium* was duly noted in the RIF group (Lopetuso,
465 Scaldaferri et al. 2013). Crucially, LEfSe analysis found that *Eubacteriumhalli*, a
466 member of this cluster, previously found to be elevated in human obesity, is a RIF
467 biomarker (Sanz, Santacruz et al. 2008, Verdam, Fuentes et al. 2013). Strikingly,
468 the RIF group had the highest levels of the *Erysipelotrichaceae* (phylum
469 *Firmicutes*) family. In contrast, it was almost absent in the two groups. Elevated
470 levels of *Erysipelotrichaceae* has been linked to human obesity and has been
471 correlated to elevated levels of Tumor Necrosis Factor- α (TNF- α), a pro-
472 inflammatory cytokine involved in obesity-linked insulin resistance (Kaakoush
473 2015). Tellingly, a high relative abundance of *Firmicutes* has been shown to
474 correlate with increased levels of peripheral TNF- α (Orbe-Orihuela, Lagunas-
475 MartÃ-nez et al. 2018). A rodent study found that a high-fat diet first increased the
476 phylum *Firmicutes*, corresponding with the changes of Paneth cell-antimicrobial
477 peptides, which was later followed by the elevations of circulating inflammatory
478 cytokines, including TNF- α , thus establishing causality between the phylum
479 *Firmicutes* and TNF- α (Guo, Li et al. 2017).

480 Therefore, precisely, we postulate that the phylum *Firmicutes* generates TNF- α -
481 driven systemic inflammation, and consequent insulin resistance may cause RIF.

482 Strikingly, investigators showed elevated TNF- α /IL-10 ratio correlates with an
483 increased risk of IVF failure (Winger, Reed et al. 2011). Chan *et al.* found that
484 insulin resistance reduces implantation rate in *in vitro* maturation-*in vitro*
485 fertilization-embryo transfer cycle (Chang, Han et al. 2013). Metformin, known to
486 reduce the F/B ratio, has been shown to increase pregnancy rate in IVF repeaters
487 without polycystic ovary syndrome (Jinno, Watanabe et al. 2010, Wang, Saha et al.
488 2018). Investigator showed an arginine-rich diet, known to reduce obesity and
489 increase insulin sensitivity, corrects the elevated F/B ratio and increases embryo
490 survival (Dai, Wu et al. 2011).

491 The most striking phyla level changed in the UE group involved depletion of
492 *Actinobacteria* and abundance of *Proteobacteria*, the pro-inflammatory phylum,
493 comprising common pathogens (e.g., *Escherichia*, *Salmonella*) (Sekirov, Russell et
494 al. 2010). Compared to the controls, only marginal changes occurred in the levels
495 of phyla *Firmicutes* and *Bacteroidetes* in this group, suggesting a critical role of
496 *Proteobacteria* phyla in UE. This concurs with the fact that *Bifidobacterium*, a
497 genus of the depleted phyla *Actinobacteria*, inhibits gut pathogens (Azad, Sarker et
498 al. 2018). Unsurprisingly, compared to the other two groups, the UE group had the
499 highest enrichment of pathogenic Gram-negative families, whose outer membrane
500 contains a unique component, lipopolysaccharide (LPS) (Brown 2019). These
501 bacterial families included: *Bacteroidaceae* (phylum *Bacteroidetes*),

502 *Veillonellaceae* (phylum *Firmicutes*) and *Enterobacteriaceae* (phylum
503 *Bacteroidetes*). Cogently, LEfSe analysis revealed members of the *Negativicutes*
504 class—such as *Veillonellaceae*, *Selenomonadales*, which are atypical gram-
505 negative *Firmicutes*, which possess lipopolysaccharides in the outer membranes—
506 were biomarkers of UE (Vesth, Ozen et al. 2013).

507 The abundance of *Negativicutes* has been linked with an increase in the systemic
508 levels of IL-6, the pro-inflammatory cytokine (Leite, Rodrigues et al. 2017). Along
509 this line, enrichment of other Gram-negative species has been shown to increase
510 plasma IL-6 levels (de Man, van Kooten et al. 1989, Leite, Rodrigues et al. 2017,
511 Higuchi, Rodrigues et al. 2018). LPS of Gram-negative species, a pro-
512 inflammatory endotoxin, binds to TLR-4 in the gastrointestinal mucosa, triggering
513 an inflammatory cascade that causes localised NF- κ B activation, ensuing the
514 systemic secretion of IL-6 (Steimle, Michaelis et al. 2019).

515 Taken together, we proffer that in the setting of the enfeebled mucosal barrier, the
516 overload of Gram-negative bacteria activates the gut innate immune system,
517 generating IL-6-driven systemic low-grade inflammation, ultimately leading to
518 UE. Indeed, Demir *et al.* found higher serum IL-6 levels, but not TNF- α levels, in
519 women with UE than fertile women (Demir, Guven et al. 2009). Since elevated IL-
520 6 levels impair various aspects of reproductive physiology, including LH secretion,
521 LH-induced ovulation, and FSH-stimulated E2 and progesterone release, the gut

522 bacteria-induced higher IL-6 levels may thus cause UE through these mechanisms
523 (Demir, Guven et al. 2009).

524 In the infertile cohort, fascinatingly, elevated levels of *Hungatella*, producers of
525 trimethylamine N-oxide (TMAO), which enhances thrombotic potential through
526 platelet hyperreactivity, were found than the controls (Zhu, Gregory et al. 2016,
527 Genoni, Christophersen et al. 2019). This data raises the possibility that an
528 overactive coagulation system is a common mechanism of implantation failure.
529 Since levels of *Hungatella* were highest in the UE group, this indicates an
530 important role of thrombosis in UE. Indeed, Azem *et al.* found inherited
531 thrombophilia plays a role in repeated IVF failures, particularly in the subgroup
532 with UE (Azem, Maslovich et al. 2001).

533 Regarding the landscape of the vaginal microbiota, data showed that the vaginal
534 bacterial community was less diverse than in the gut. Rarefaction analysis found
535 that the RIF group had the lowest microbial diversity of the three groups,
536 suggesting a healthy vaginal microbiota in the RIF group (Lokken, Richardson et
537 al. 2019). We posit that through TNF- α -driven systemic insulin resistance, gut
538 dysbiosis in the RIF group causes hyperglycemia and consequently increases
539 glycogen levels in the vaginal epithelium, which is required for the maintenance of
540 healthy microbiota (Carrara, Bazotte et al. 2009, Amabebe and Anumba 2018).
541 Alternatively, adipose tissue-driven rise in peripheral estrogen may increase the

542 glycogen content of vaginal epithelial cells (Lokken, Richardson et al. 2019). This
543 chimes with the finding that obesity protects against vaginal dysbiosis (Lokken,
544 Richardson et al. 2019). By contrast, the highest microbial diversity in the control
545 group suggests vaginal dysbiosis. LEfSe analysis found *Leptotrichia*, an
546 opportunistic pathogen of the female urogenital tract of the phylum *Fusobacteria*,
547 in this group (Thilesen, Nicolaidis et al. 2007). In line with this, other pathogenic
548 genera such as *Gardnerella*, *Prevotella*, and *Snaethia* were relatively more
549 abundant in the controls compared to the infertile groups (Thilesen, Nicolaidis et
550 al. 2007, Amabebe and Anumba 2018).

551 Consistent with previous research, *Firmicutes*, mainly *Lactobacilli* spp.,
552 constituted the bulk of total bacteria of all the groups (Madhivanan, Raphael et al.
553 2014, Madhivanan, Alleyn et al. 2015). Of the nine detected *Lactobacilli* spp., four
554 belonged to the *L. delbrueckii*, subsp. of the *L. acidophilus* group (*L. iners*,
555 *L.gasseri*, *L. jensenii*, *L. equicursoris*), three belonged to the *L. reuteri* group (*L.*
556 *fermentum*, *L. reuteri*, *L. vaginalis*), and two belonged to the *L. salivarius* group
557 (*L.ruminis*, *L. salivarius*) (Salvetti, Torriani et al. 2012). Of the three groups, the *L.*
558 *reuteri* group comprises mostly obligate heterofermentative lactobacilli, consistent
559 with the finding that compared to the women in the USA, Indian women housed a
560 higher proportion of obligate heterofermentative lactobacilli, reflecting a need for
561 metabolic plasticity and an adaptation against high pathogen load (Salvetti,

562 Torriani et al. 2012, Madhivanan, Raphael et al. 2014, Madhivanan, Alleyn et al.
563 2015). Three *Lactobacillus* species dominated the vaginal microbiota across the
564 groups: *L. iners*, *L.gasseri*, and *L.ruminis*, with *L. iners* being the most abundant,
565 suggesting the existence of community state type 3 (CST 3) of the five human
566 vaginal microbial communities (HVMC) as classified by Ravel et al. (2011)
567 (Ravel, Gajer et al. 2011). To put this in context, *L. crispatus*, *L. jensenii*, *L.*
568 *gasseri*, and *L. iners* occur most frequently in the healthy vagina worldwide,
569 although substantial geographic, socio-economic and ethnic variations exist
570 (Madhivanan, Krupp et al. 2008, Madhivanan, Raphael et al. 2014).

571 By lowering the vaginal PH<4 through lactic acid, generating bacteriocins and
572 hydrogen peroxide (H₂O₂), or acting as a competitive inhibitor, *Lactobacilli* spp.
573 protect the vagina from opportunistic pathogens (Kalia, Singh et al. 2020, Wang,
574 Fan et al. 2020). Notably, though this protection varies according to strains based
575 on their ability to produce D-lactic acid, which keeps PH<4, and antibacterial
576 compounds (Wang, Fan et al. 2020). Most studies have shown that *L. iners*,
577 lacking the ability to produce D-lactic acid, is less protective than other strains
578 such as *L. crispatus* and *L. salivarius* (Pino, Bartolo et al. 2019, Kalia, Singh et al.
579 2020, Wang, Fan et al. 2020). Indeed, the highest relative proportions of
580 *Lactobacillus iners AB-1* occurred in the UE group, suggesting a weakened
581 resistance to colonisation by pathogens (Wang, Fan et al. 2020).

582 **4.1 Conclusion**

583 In sum, we illuminated gut and vaginal bacterial communities' landscape, both at
584 broader and finer levels, in implantation failure-associated infertile women and
585 fertile women and offer conjectures to explain the data. We discovered that the
586 infertile cohort had gut dysbiosis. Most importantly, these findings suggest that gut
587 dysbiosis does not necessarily lead to vaginal dysbiosis. We hope that this study
588 has laid the foundation of research on the link between the gut microbiota, the gut-
589 reproductive microbiota axis, and implantation failure, which can lead microbiota-
590 based diagnostic tools and therapeutic strategies.

591 **4.2 Limitations**

592 Our study has a few limitations. First, since it is an underpowered single-center
593 study, multi-center longitudinal studies with a large sample size are needed.
594 Second, although we suggested the mechanistic hypotheses, we did not measure
595 alterations in the immune system, hormones, platelet parameters and bacterial
596 metabolic products such as short-chain fatty acids. Third, owing to the limited
597 resolution of the 16S rRNA-sequencing technique, we could not identify what
598 specific bacterial species or strains were involved. Fourth, we have not controlled
599 for the factors that influence the vaginal microbiota such as menses, vaginal
600 douching, and contraception. Finally, the functional significance of many species
601 such as *peptoniphilus* remains undetermined in our analysis as the literature is

602 scant on these genera. Hence, future investigations should address these
603 shortcomings.

604

605 **References**

606 Al-Assal, K., A. C. Martinez, R. S. Torrinhas, C. Cardinelli and D. Waitzberg (2018). "Gut
607 microbiota and obesity." *Clinical Nutrition Experimental* **20**: 60-64.

608 Al-Nasiry, S., E. Ambrosino, M. Schlaepfer, S. A. Morré, L. Wieten, J. W. Voncken, M.
609 Spinelli, M. Mueller and B. W. Kramer (2020). "The Interplay Between Reproductive Tract
610 Microbiota and Immunological System in Human Reproduction." *Frontiers in immunology* **11**:
611 378-378.

612 Alexander, K. L., S. R. Targan and C. O. Elson, 3rd (2014). "Microbiota activation and
613 regulation of innate and adaptive immunity." *Immunological reviews* **260**(1): 206-220.

614 Amabebe, E. and D. O. C. Anumba (2018). "The Vaginal Microenvironment: The Physiologic
615 Role of Lactobacilli." *Frontiers in medicine* **5**: 181-181.

616 Azad, M. A. K., M. Sarker, T. Li and J. Yin (2018). "Probiotic Species in the Modulation of Gut
617 Microbiota: An Overview." *BioMed research international* **2018**: 9478630-9478630.

618 Azem, F., S. Maslovich, A. Amit, J. B. Lessing, M. J. Kupferminc and A. Many (2001).
619 "Increased rates of thrombophilia in women with repeated in-vitro fertilization-embryo transfer
620 (IVF-ET) failures." *Fertility and Sterility* **76**(3): S226.

621 Baker, J. M., L. Al-Nakkash and M. M. Herbst-Kralovetz (2017). "Estrogen–gut microbiome
622 axis: Physiological and clinical implications." *Maturitas* **103**: 45-53.

623 Bellver, J., S. R. Soares, C. Alvarez, E. Munoz, A. Ramirez, C. Rubio, V. Serra, J. Remohi and
624 A. Pellicer (2008). "The role of thrombophilia and thyroid autoimmunity in unexplained
625 infertility, implantation failure and recurrent spontaneous abortion." *Hum Reprod* **23**(2): 278-
626 284.

627 Brown, G. C. (2019). "The endotoxin hypothesis of neurodegeneration." *Journal of*
628 *Neuroinflammation* **16**(1): 180.

629 Budden, K. F., S. L. Gellatly, D. L. A. Wood, M. A. Cooper, M. Morrison, P. Hugenholtz and P.
630 M. Hansbro (2017). "Emerging pathogenic links between microbiota and the gut–lung axis."
631 *Nature Reviews Microbiology* **15**(1): 55-63.

632 Carrara, M. A., R. B. Bazotte, L. Donatti, T. I. Svidzinski, M. E. Consolaro, E. V. Patussi and M.
633 R. Batista (2009). "Effect of experimental diabetes on the development and maintenance of
634 vulvovaginal candidiasis in female rats." *Am J Obstet Gynecol* **200**(6): 659 e651-654.

635 Chang, E. M., J. E. Han, H. H. Seok, D. R. Lee, T. K. Yoon and W. S. Lee (2013). "Insulin
636 resistance does not affect early embryo development but lowers implantation rate in in vitro
637 maturation–in vitro fertilization–embryo transfer cycle." *Clinical Endocrinology* **79**(1): 93-99.

638 Cho, S. H., J. H. Kim, H. J. An, J. O. Kim, Y. R. Kim, W. S. Lee and N. K. Kim (2019).
639 "Association of methionine synthase (rs1805087), methionine synthase reductase (rs1801394),
640 and methylenetetrahydrofolate dehydrogenase 1 (rs2236225) genetic polymorphisms with
641 recurrent implantation failure." *Hum Fertil (Camb)*: 1-8.

642 Christiansen, O. B., H. S. Nielsen, A. Kolte and A. T. Pedersen (2006). "Research methodology
643 and epidemiology of relevance in recurrent pregnancy loss." *Semin Reprod Med* **24**(1): 5-16.

644 Christiansen, O. B., H. S. Nielsen and A. M. Kolte (2006). "Future directions of failed
645 implantation and recurrent miscarriage research." *Reprod Biomed Online* **13**(1): 71-83.

646 Dai, Z.-L., G. Wu and W.-Y. Zhu (2011). "Amino acid metabolism in intestinal bacteria: links
647 between gut ecology and host health." *Frontiers in bioscience (Landmark edition)* **16**: 1768-
648 1786.

649 de Man, P., C. van Kooten, L. Aarden, I. Engberg, H. Linder and C. Svanborg Edén (1989).
650 "Interleukin-6 induced at mucosal surfaces by gram-negative bacterial infection." *Infection and*
651 *immunity* **57**(11): 3383-3388.

652 Demir, B., S. Guven, E. S. G. Guven, Y. Atamer and T. Gul (2009). "Serum IL-6 level may have
653 role in the pathophysiology of unexplained infertility." *American journal of reproductive*
654 *immunology* (New York, N.Y. : 1989) **62**(4): 261-267.

655 El Hachem, H., V. Crepaux, P. May-Panloup, P. Descamps, G. Legendre and P.-E. Bouet (2017).
656 "Recurrent pregnancy loss: current perspectives." *International journal of women's health* **9**: 331-
657 345.

658 Genoni, A., C. T. Christophersen, J. Lo, M. Coghlan, M. C. Boyce, A. R. Bird, P. Lyons-Wall
659 and A. Devine (2019). "Long-term Paleolithic diet is associated with lower resistant starch
660 intake, different gut microbiota composition and increased serum TMAO concentrations."
661 *European Journal of Nutrition*.

662 Graham, R. A., M. W. Seif, J. D. Aplin, T. C. Li, I. D. Cooke, A. W. Rogers and P. Dockery
663 (1990). "An endometrial factor in unexplained infertility." *BMJ* (Clinical research ed.)
664 **300**(6737): 1428-1431.

665 Guo, X., J. Li, R. Tang, G. Zhang, H. Zeng, R. J. Wood and Z. Liu (2017). "High Fat Diet Alters
666 Gut Microbiota and the Expression of Paneth Cell-Antimicrobial Peptides Preceding Changes of
667 Circulating Inflammatory Cytokines." *Mediators of inflammation* **2017**: 9474896-9474896.

668 Hernández-Vargas, P., M. Muñoz and F. Domínguez (2020). "Identifying biomarkers for
669 predicting successful embryo implantation: applying single to multi-OMICs to improve
670 reproductive outcomes." *Human Reproduction Update* **26**(2): 264-301.

671 Higuchi, B. S., N. Rodrigues, M. I. Gonzaga, J. C. C. Paiolo, N. Stefanutto, W. P. Omori, D. G.
672 Pinheiro, J. L. Brisotti, E. Matheucci, Jr., V. S. Mariano and G. L. V. de Oliveira (2018).
673 "Intestinal Dysbiosis in Autoimmune Diabetes Is Correlated With Poor Glycemic Control and
674 Increased Interleukin-6: A Pilot Study." *Frontiers in immunology* **9**: 1689-1689.

675 Jang, H. B., M.-K. Choi, J. H. Kang, S. I. Park and H.-J. Lee (2017). "Association of dietary
676 patterns with the fecal microbiota in Korean adolescents." *BMC Nutrition* **3**(1): 20.

677 Jennings, A., M. Koch, M. K. Jensen, C. Bang, J. Kassubek, H.-P. Müller, U. Nöthlings, A.
678 Franke, W. Lieb and A. Cassidy (2019). "The role of the gut microbiome in the association
679 between habitual anthocyanin intake and visceral abdominal fat in population-level analysis."
680 *The American Journal of Clinical Nutrition* **111**(2): 340-350.

681 Jinno, M., A. Watanabe, N. Eguchi, N. Hatakeyama, J. Hirohama and E. Hiura (2010). "Low-
682 dose metformin improves pregnancy rate in IVF repeaters without polycystic ovary syndrome:
683 its indication and mechanism." *Fertility and Sterility* **94**(4): S29.

684 Kaakoush, N. O. (2015). "Insights into the Role of Erysipelotrichaceae in the Human Host."
685 *Frontiers in cellular and infection microbiology* **5**: 84-84.

686 Kalia, N., J. Singh and M. Kaur (2020). "Microbiota in vaginal health and pathogenesis of
687 recurrent vulvovaginal infections: a critical review." *Annals of Clinical Microbiology and*
688 *Antimicrobials* **19**(1): 5.

689 Kamel, R. M. (2010). "Management of the infertile couple: an evidence-based protocol."
690 *Reproductive biology and endocrinology : RB&E* **8**: 21-21.

691 Koliada, A., G. Syzenko, V. Moseiko, L. Budovska, K. Puchkov, V. Perederiy, Y. Gavalko, A.
692 Dorofeyev, M. Romanenko, S. Tkach, L. Sineok, O. Lushchak and A. Vaiserman (2017).
693 "Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian
694 population." *BMC microbiology* **17**(1): 120-120.

695 Le Chatelier, E., T. Nielsen, J. Qin, E. Prifti, F. Hildebrand, G. Falony, M. Almeida, M.
696 Arumugam, J.-M. Batto, S. Kennedy, P. Leonard, J. Li, K. Burgdorf, N. Grarup, T. Jørgensen, I.
697 Brandslund, H. B. Nielsen, A. S. Juncker, M. Bertalan, F. Levenez, N. Pons, S. Rasmussen, S.
698 Sunagawa, J. Tap, S. Tims, E. G. Zoetendal, S. Brunak, K. Clément, J. Doré, M. Kleerebezem,
699 K. Kristiansen, P. Renault, T. Sicheritz-Ponten, W. M. de Vos, J.-D. Zucker, J. Raes, T. Hansen,
700 H. I. T. c. Meta, P. Bork, J. Wang, S. D. Ehrlich and O. Pedersen (2013). "Richness of human
701 gut microbiome correlates with metabolic markers." *Nature* **500**(7464): 541-546.

702 Leite, A. Z., N. d. C. Rodrigues, M. I. Gonzaga, J. C. C. Paiolo, C. A. de Souza, N. A. V.
703 Stefanutto, W. P. Omori, D. G. Pinheiro, J. L. Brisotti, E. Matheucci Junior, V. S. Mariano and
704 G. L. V. de Oliveira (2017). "Detection of Increased Plasma Interleukin-6 Levels and Prevalence
705 of *Prevotella copri* and *Bacteroides vulgatus* in the Feces of Type 2 Diabetes Patients." *Frontiers*
706 *in immunology* **8**: 1107-1107.

707 Lindsay, T. J. and K. R. Vitrikas (2015). "Evaluation and treatment of infertility." *American*
708 *family physician* **91**(5): 308-314.

709 Lokken, E. M., B. A. Richardson, J. Kinuthia, K. Mwinyikai, A. Abdalla, W. Jaoko, K.
710 Mandaliya, J. Shafi and R. Scott McClelland (2019). "A Prospective Cohort Study of the
711 Association Between Body Mass Index and Incident Bacterial Vaginosis." *Sexually transmitted*
712 *diseases* **46**(1): 31-36.

713 Lopetuso, L. R., F. Scaldaferri, V. Petito and A. Gasbarrini (2013). "Commensal Clostridia:
714 leading players in the maintenance of gut homeostasis." *Gut pathogens* **5**(1): 23-23.

715 Madhivanan, P., H. N. Alleyn, E. Raphael, K. Krupp, K. Ravi, R. Nebhrajani, A. Arun, A. L.
716 Reingold, L. W. Riley and J. D. Klausner (2015). "Identification of culturable vaginal
717 *Lactobacillus* species among reproductive age women in Mysore, India." *J Med Microbiol* **64**(6):
718 636-641.

719 Madhivanan, P., K. Krupp, V. Chandrasekaran, C. Karat, A. Arun, C. R. Cohen, A. L. Reingold
720 and J. D. Klausner (2008). "Prevalence and correlates of bacterial vaginosis among young
721 women of reproductive age in Mysore, India." *Indian J Med Microbiol* **26**(2): 132-137.

722 Madhivanan, P., E. Raphael, A. Rumphs, K. Krupp, K. Ravi, V. Srinivas, A. Arun, A. L.
723 Reingold, J. D. Klausner and L. W. Riley (2014). "Characterization of culturable vaginal
724 *Lactobacillus* species among women with and without bacterial vaginosis from the United States
725 and India: a cross-sectional study." *Journal of medical microbiology* **63**(Pt 7): 931-935.

726 Mahajan, K. and A. Batra (2018). "Obesity in adult asian indians- the ideal BMI cut-off." *Indian*
727 *heart journal* **70**(1): 195-195.

728 Matijašić, B. B., T. Obermajer, L. Lipoglavšek, I. Grabnar, G. Avguštin and I. Rogelj (2014).
729 "Association of dietary type with fecal microbiota in vegetarians and omnivores in Slovenia."
730 *European Journal of Nutrition* **53**(4): 1051-1064.

731 Mejía-León, M. E. and A. M. C. d. I. Barca (2015). "Diet, Microbiota and Immune System in
732 Type 1 Diabetes Development and Evolution." *Nutrients* **7**(11): 9171-9184.

733 Moreno, I., F. M. Codoñer, F. Vilella, D. Valbuena, J. F. Martinez-Blanch, J. Jimenez-Almazán,
734 R. Alonso, P. Alamá, J. Remohí, A. Pellicer, D. Ramon and C. Simon (2016). "Evidence that the
735 endometrial microbiota has an effect on implantation success or failure." *Am J Obstet Gynecol*
736 **215**(6): 684-703.

737 Okumura, R. and K. Takeda (2017). "Roles of intestinal epithelial cells in the maintenance of gut
738 homeostasis." *Experimental & Molecular Medicine* **49**(5): e338-e338.

739 Orbe-Orihuela, Y. C., A. Lagunas-Martínez, M. Bahena-Román, V. Madrid-Marina, K.
740 Torres-Poveda, E. Flores-Alfaro, A. Mández-Padrón, C. E. Díaz-Benitez, O. Peralta-

741 Zaragoza, D. Ant nez-Ortiz, M. Cruz and A. I. Burguete-Garc a (2018). "High relative
742 abundance of firmicutes and increased TNF-  levels correlate with obesity in children." *Salud*
743 *Publica Mex.* 2018; 60(1): 5-11.

744 Ott, S. J. and S. Schreiber (2006). "Reduced microbial diversity in inflammatory bowel diseases."
745 *Gut* **55**(8): 1207-1207.

746 Pino, A., E. Bartolo, C. Caggia, A. Cianci and C. L. Randazzo (2019). "Detection of vaginal
747 lactobacilli as probiotic candidates." *Scientific Reports* **9**(1): 3355.

748 Polanski, L. T., M. N. Baumgarten, S. Quenby, J. Brosens, B. K. Campbell and N. J. Raine-
749 Fenning (2014). "What exactly do we mean by 'recurrent implantation failure'? A systematic
750 review and opinion." *Reproductive BioMedicine Online* **28**(4): 409-423.

751 Ravel, J. and R. M. Brotman (2016). "Translating the vaginal microbiome: gaps and challenges."
752 *Genome medicine* **8**(1): 35-35.

753 Ravel, J., P. Gajer, Z. Abdo, G. M. Schneider, S. S. K. Koenig, S. L. McCulle, S. Karlebach, R.
754 Gorle, J. Russell, C. O. Tacket, R. M. Brotman, C. C. Davis, K. Ault, L. Peralta and L. J. Forney
755 (2011). "Vaginal microbiome of reproductive-age women." *Proceedings of the National*
756 *Academy of Sciences of the United States of America* **108 Suppl 1**(Suppl 1): 4680-4687.

757 Salvetti, E., S. Torriani and G. E. Felis (2012). "The Genus *Lactobacillus*: A Taxonomic
758 Update." *Probiotics Antimicrob Proteins* **4**(4): 217-226.

759 Sanz, Y., A. Santacruz and G. De Palma (2008). "Insights into the roles of gut microbes in
760 obesity." *Interdisciplinary perspectives on infectious diseases* **2008**: 829101-829101.

761 Sekirov, I., S. L. Russell, L. C. M. Antunes and B. B. Finlay (2010). "Gut Microbiota in Health
762 and Disease." *Physiological Reviews* **90**(3): 859-904.

763 Simon, A. and N. Laufer (2012). "Assessment and treatment of repeated implantation failure
764 (RIF)." *Journal of assisted reproduction and genetics* **29**(11): 1227-1239.

765 Steimle, A., L. Michaelis, F. Di Lorenzo, T. Kliem, T. M nznner, J. K. Maerz, A. Sch fer, A.
766 Lange, R. Parusel, K. Gronbach, K. Fuchs, A. Silipo, H. H.  z, B. J. Pichler, I. B. Autenrieth, A.
767 Molinaro and J.-S. Frick (2019). "Weak Agonistic LPS Restores Intestinal Immune
768 Homeostasis." *Molecular therapy : the journal of the American Society of Gene Therapy* **27**(11):
769 1974-1991.

770 Tersigni, C., S. D'Ippolito, F. Di Nicuolo, R. Marana, V. Valenza, V. Masciullo, F. Scaldaferrri,
771 F. Malatucca, C. de Waure, A. Gasbarrini, G. Scambia and N. Di Simone (2018). "Recurrent
772 pregnancy loss is associated to leaky gut: a novel pathogenic model of endometrium
773 inflammation?" *Journal of translational medicine* **16**(1): 102-102.

774 Thiesen, C. M., M. Nicolaidis, J. E. L keb , E. Falsen, A. T. Jorde and F. M ller (2007).
775 "*Leptotrichia amnionii*, an emerging pathogen of the female urogenital tract." *Journal of clinical*
776 *microbiology* **45**(7): 2344-2347.

777 Uchida, M., E. Oyanagi, N. Kawanishi, M. Iemitsu, M. Miyachi, M. J. Kremenik, S. Onodera
778 and H. Yano (2014). "Exhaustive exercise increases the TNF-  production in response to
779 flagellin via the upregulation of toll-like receptor 5 in the large intestine in mice." *Immunology*
780 *letters* **158**(1-2): 151-158.

781 Verdam, F. J., S. Fuentes, C. de Jonge, E. G. Zoetendal, R. Erbil, J. W. Greve, W. A. Buurman,
782 W. M. de Vos and S. S. Rensen (2013). "Human intestinal microbiota composition is associated
783 with local and systemic inflammation in obesity." *Obesity* **21**(12): E607-E615.

784 Vesth, T., A. Ozen, S. C. Andersen, R. S. Kaas, O. Lukjancenko, J. Bohlin, I. Nookaew, T. M.
785 Wassenaar and D. W. Ussery (2013). "*Veillonella*, Firmicutes: Microbes disguised as Gram
786 negatives." *Standards in genomic sciences* **9**(2): 431-448.

787 Vinchi, F. (2019). "Thrombosis Prevention: Let's Drug the Microbiome!" *HemaSphere* **3**(1):
788 e165-e165.

789 Vital, M., A. Karch and D. H. Pieper (2017). "Colonic Butyrate-Producing Communities in
790 Humans: an Overview Using Omics Data." *mSystems* **2**(6): e00130-00117.

791 Wang, C., A. Fan, H. Li, Y. Yan, W. Qi, Y. Wang, C. Han and F. Xue (2020). "Vaginal bacterial
792 profiles of aerobic vaginitis: a case-control study." *Diagnostic Microbiology and Infectious
793 Disease* **96**(4): 114981.

794 Wang, M., S. Wichienchot, X. He, X. Fu, Q. Huang and B. Zhang (2019). "In vitro colonic
795 fermentation of dietary fibers: Fermentation rate, short-chain fatty acid production and changes
796 in microbiota." *Trends in Food Science & Technology* **88**: 1-9.

797 Wang, Z., S. Saha, S. Van Horn, E. Thomas, C. Traini, G. Sathe, D. K. Rajpal and J. R. Brown
798 (2018). "Gut microbiome differences between metformin- and liraglutide-treated T2DM
799 subjects." *Endocrinol Diabetes Metab* **1**(1): e00009.

800 Winger, E. E., J. L. Reed, S. Ashoush, T. El-Toukhy, S. Ahuja and M. Taranissi (2011). "Degree
801 of TNF- α /IL-10 Cytokine Elevation Correlates With IVF Success Rates in Women Undergoing
802 Treatment With Adalimumab (Humira) and IVIG." *American Journal of Reproductive
803 Immunology* **65**(6): 610-618.

804 Witkin, S. S., K. M. Sultan, G. S. Neal, J. Jeremias, J. A. Grifo and Z. Rosenwaks (1994).
805 "Unsuspected Chlamydia trachomatis infection and in vitro fertilization outcome." *American
806 Journal of Obstetrics and Gynecology* **171**(5): 1208-1214.

807 Zhang, J., H. Liu, X. Mao, Q. Chen, Y. Fan, Y. Xiao, Y. Wang and Y. Kuang (2019). "Effect of
808 body mass index on pregnancy outcomes in a freeze-all policy: an analysis of 22,043 first
809 autologous frozen-thawed embryo transfer cycles in China." *BMC Medicine* **17**(1): 114.

810 Zhu, W., J. C. Gregory, E. Org, J. A. Buffa, N. Gupta, Z. Wang, L. Li, X. Fu, Y. Wu, M.
811 Mehrabian, R. B. Sartor, T. M. McIntyre, R. L. Silverstein, W. H. W. Tang, J. A. DiDonato, J.
812 M. Brown, A. J. Lusis and S. L. Hazen (2016). "Gut Microbial Metabolite TMAO Enhances
813 Platelet Hyperreactivity and Thrombosis Risk." *Cell* **165**(1): 111-124.

814

815 We presented a portion of the data of this study in
816 the 4th World Congress on Recurrent Pregnancy Loss (WCRPL 2019) in
817 Jerusalem, Israel.

818

819 **Acknowledgements:**

820 The authors wish to acknowledge the technical support of Nitin Savaliya, of
821 Gujarat Biotechnology Research Centre (GBRC), for fecal and vaginal samples
822 sequencing run. We are also grateful to Dr Yuvraj Jadeja, Dr Nipa Shah, Dr Nikita
823 Daswani, Hansa Khrishti and Harmi Thakkar for supporting the clinical work.

824 **Availability of data and materials:**

825 The 16S rRNA gene sequencing data for all the gut and vaginal microbiota
826 samples analyzed in this study have been deposited with the National Center for
827 Biotechnology Information (NCBI): reference number PRJNA7020230.

828

829

830 **Authors' contributions:**

831

832 BP conceptualized the idea, contributed to the design, made a few suggestions on
833 the statistical methods, interpreted the data, and wrote the manuscript except for
834 the metagenomics part of the method section. NP contributed to the design, patient
835 identification, sample collection, ethical approval, financially supported the clinical
836 work, presented a part of the work, and critically discussed and corrected the
837 manuscript's clinical aspects. NP collected fecal and vaginal samples, performed
838 DNA isolation, sequencing, assisted in the analysis, drafted a part of the material
839 and method section, and prepared some graphs and tables. SP collected fecal and
840 vaginal samples, performed DNA isolation, library preparation of samples, and
841 contributed to the correction of materials and method section. NN analysed the
842 metagenomics data and contributed to the writing of the metagenomics section of
843 the manuscript. RP sequenced fecal samples and corrected material and method
844 section. CJ, the director of GBRC, provided financial and technical support and
845 guidance for metagenomics sequencing and critically discussed the data. NP and
846 MP contributed to ethical permission, patient selection and clinical data acquisition
847 and critically discussed the data. All the authors provided criticisms and read and
848 approved the manuscript.

849

850 **Funding:**

851 No external source of funding. The clinical aspect of this work was funded by Dr.
852 Nayna Patel, the director of Akanksha Hospital and Research Institute. The
853 metagenomics aspect of the study was funded by Dr. Chaitanya Joshi, the director
854 of Gujarat Biotechnology Research Centre (GBRC). We report no conflict of
855 interest.

856

857 **Competing interests:**

858 The authors declare no competing interests.

859

860 **Consent for publication:**

861 All authors have given their consent for the publication of this manuscript.

862 **Figure and Table Legend**

863

864 **Table 1.** Study characteristics of the control, RIF, and the UE groups. Data are
865 expressed as the mean \pm SD or n/N (%).RIF, recurrent implantation failure; UE,
866 unexplained infertility; BMI, body–mass index; Veg, Vegetarian; NA, Not
867 applicable. Differences between the 3 groups were assessed by 1-factor ANOVA
868 and Tukey’s multiple comparison test was used for post-hoc comparisons, if
869 $P < 0.05$. In the RIF group, two participants belonged to the RPL category. a.
870 statistically significant difference between CON and RIF.

871

872 **Figure 1.** Box plots of α -diversity indices of the gut bacterial microbiomes of the
873 control (CON, N = 11), RIF (RIF, N = 10), and the UE (UE, N=10) groups: (a)
874 Shannon and (b) Chao 1 indices. The P values were determined by the Kruskal-
875 Wallis test.

876

877 **Figure 2.** Differences in community composition (β -diversity) between the control
878 (CON, Red, N = 11), RIF (RIF, Green, N = 10), and the UE group (UE, Cyan
879 N=10) groups. Comparisons are based on the PCoA plots of Bray-Curtis (left) and
880 Jaccard distances (right). Each principal coordinate axis represents the proportion
881 of variance. Non-parametric multivariate analysis of variance (PERMANOVA)

882 was used to calculate statistical differences between the groups. In the Bray-Curtis-
883 based PCoA, the first and second axes of the PCoA accounted for 21.5% of the
884 total variance (PERMANOVA, $P < 0.05$, $R^2 = 0.12$). In the Jaccard based PCoA, the
885 first and second axes explained 23.4% of the total variance (PERMANOVA,
886 $P < 0.05$, $R^2 = 0.10$).

887

888 **Figure 3.** The bar chart shows the comparisons of relative abundances of top gut
889 bacterial taxa between control (CON, $N = 11$), RIF (RIF, $N = 10$), and the UE (UE,
890 $N=10$) groups at (a) the phylum (b) family and (c) genus levels. No differences in
891 relative abundance were found between the phylum and family levels ($P > 0.05$,
892 Kruskal-Wallis test). Six bacterial genera showed statistically significantly
893 ($P < 0.05$, Kruskal-wallis test) differential abundance across the three groups are
894 shown.

895

896 **Figure 4.** Distinct taxa of the gut bacteria determined by linear discriminant
897 analysis effect size (LEfSe) analysis in the control (CON, $N = 11$), RIF (RIF, $N =$
898 10), and the UE (UE, $N=10$) groups. (a) The cladogram shows the taxa that were
899 significantly elevated between the groups (b) Taxa with an LDA score significant
900 threshold > 3 are shown ($P < .05$; LDA score > 3).

901

902 **Figure 5.** The bar charts show taxonomic comparisons of the vaginal bacteria
903 between the control (CON, N = 8), RIF (RIF, N = 8), and the UE (UE, N=8)
904 groups at (a) the phylum, (b) family (c) genus level (d) species levels. No
905 differences in relative abundance were found at any levels ($P > 0.05$, Kruskal-
906 Wallis test).

907

908 Figure 6. Differentially abundant vagina bacteria between the control (CON, N =
909 8), RIF (RIF, N = 8), and the UE (UE, N=8) groups as determined by linear
910 discriminant analysis effect size (LEfSe) analysis. Taxa with a LDA score
911 significant threshold >3 are shown ($P < .05$; LDA score 3).

912

913 **Figure 7.** The bar charts show taxonomic comparisons of different *Lactobacillus*
914 spp. of the vagina between the control (CON, N = 8), RIF (RIF, N = 8), and the UE
915 (UE, N=8) groups. No significant differences in relative abundance were found
916 between at any levels ($P > 0.05$, Kruskal-Wallis test).

917

918

919 **Supplementary figures**

920 **Figure 1S.** Rarefaction analysis of Gut and Vaginal Microbial diversity of the
921 controls, RIF and UE groups. (A) Rarefaction curve of α -diversity of the gut
922 bacteria in control (CON, N = 11), RIF (RIF, N = 10), and the UE (UE, N=10)
923 groups (B) Rarefaction curve of α -diversity of the vaginal bacteria in control
924 (CON, N = 8), RIF (RIF, N = 8), and the UE (UE, N=8) groups. The x-axis shows
925 the number of sequences per sample, and the y-axis shows the rarefaction measure.
926 When the curve plateaus, it shows that the sequencing data volume is sufficient to
927 reveal most of the microbial information in the sample. The values of the y-axis
928 reflect the community diversity of microbiota. The sequence number in the chart
929 shows the sequence number of the sample. OTU, operational taxonomic unit.

930
931 **Figure 2S.** Rarefaction analysis of microbiome diversity sequences per sample: (a)
932 gut (n=31) and (b) vaginal samples (n=24) (Operational taxonomic units (OTUs)
933 for each sample at 97% of similarity). Each graph represents mean (column) and
934 SD (bars).

935
936 **Figure 3S.** Influence of diet on α -diversity between vegetarian (n=21) and non-
937 vegetarian participants (n=10). No significant difference in α -diversity between
938 these groups was found ($P > 0.05$, the Mann-Whitney U test).

939 **Figure 4S.** The bar chart shows taxonomic comparisons of the gut bacteria
940 between the controls (CON, N=11) and the infertile cohort (the RIF plus UE
941 groups, N=20) at the genus level with statistical significance values ($P > 0.05$,
942 Mann-Whitney U test).

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

Table 1

Characteristics	Control (n=11)		RIF (n=10)		UE (n=10)	
Age (Years)	27.9±3.8		34.5±4.8 ^a		30.8±3.42	
BMI (kg/m ²)	21.62±4.05		25.9±3.31 ^a		23.92±3	
Nulligravida	NA		2 (20%)		NA	
Nullipara			8 (80%)		10 (100%)	
Dietary Information	Veg	Non-Veg	Veg	Non-Veg	Veg	Non-Veg
	5 (45%)	6 (54%)	4 (40%)	6 (60%)	9 (90%)	1 (10%)

Figure 1(a)

Kruskal-Wallis , $P=0.049$; $H =6.00$




Figure 1(b)

Kruskal-Wallis , $P=0.003$; $H =11.6$




Figure 2(a),(b)





Figure 3(a)




Figure 3(b)







Figure 3(c)




Hungatella




Ruminococcaceae UCG-010




Bacteroides



Prevotella_9



Ruminococcaceae UCG-004



Sutterella

Figure 4(a)




Figure 4(b)




Figure 5(a)




Figure 5(b)




Figure 5(c)




Figure 5(d)




Figure 6





Figure 7



Supplementary figures

Figure 1S(a)




Figure 1S(b)




Figure 2S(a)




Figure 3S

Kruskal-Wallis , $P=0.150$; $H = 2.06$




Figure 4S

